The FDA rejected Capricor Therapeutics’ Duchenne cell therapy deramiocel for a second time, citing significant issues with the trial package despite a company pivot to a narrower Duchenne indication. The decision halts the treatment’s path toward market approval. The underlying development context described alongside the FDA action notes that two randomized clinical trials failed to show deramiocel could prevent heart failure or preserve upper-arm muscle function. With Duchenne patients in later stages having limited options, the rejection underscores the difficulty of meeting regulatory endpoints in the disease. For biotech strategy teams, the key operational implication is how sharply dossier-level expectations can diverge from interim sentiment after program pivots—especially when efficacy has not been demonstrated in randomized settings.